Understanding new weight-loss drugs

A newer class of medications used to treat type 2 diabetes called glucagon-like peptide-1 (GLP-1) receptor agonists has gained attention because of their impressive weight-loss results—in many cases, 10% to 20% of a person’s body weight. Versions of two of these GLP-1 receptor agonists, liraglutide (Saxenda) and semaglutide (Wegovy), are FDA-approved for weight loss, even for people without diabetes. However, there isn’t enough evidence to know whether these drugs might be beneficial or dangerous for people who are not diagnosed with diabetes or obesity.